Study Status
In Development
DAIDS Number
39258
IND Number
TBD
Primary Protocol Team Members
Summary
IMPAACT 2051 is a Phase II study of pretomanid, given to children with bedaquiline and linezolid, with or without moxifloxacin (BPaL/M), to treat drug-resistant tuberculosis. The study will evaluate the pharmacokinetics and safety while children are taking BPaL/M and for a year after completing treatment.
Site selection is expected to be open to all IMPAACT sites.
To contact the clinical research managers for this study, please email impaact.crm2051@frontierscience.org.